The Patent Finder
ER

E R Squibb and Sons LLC

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

9 patents currently held

2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in May 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
8
Ending by 2030
May 2027
Next term end
5
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Fee deadlines

No maintenance fee falls due on this company's record before Nov 10, 2027.

Recent changes

  • 4 terms have ended since Aug 18, 2026

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 9 of 9

PatentTitleStatusExpiresConfidence
US 10,441,655Monoclonal Antibodies to Programmed Death 1 (PD-1)
In force
 · High confidence
In forceHigh confidence
US 10,501,556Compositions and Methods for Treating Cocaine-Related Disorders
In force
 · High confidence
In forceHigh confidence
US 8,779,105Monoclonal Antibodies to Programmed Death 1 (PD-1)
In force
 · High confidence
In forceHigh confidence
US 7,868,140Human ANTI-B7RP1 Neutralizing Antibodies
In force
 · High confidence
In forceHigh confidence
US 8,008,449Human Monoclonal Antibodies to Programmed Death 1(PD-1) and Methods for Treating Cancer Using ANTI-PD-1 Antibodies Alone or in Combination with Other Immunotherapeutics
In force
 · High confidence
In forceHigh confidence
US 8,981,071Human anti-B7RP1 Neutralizing Antibodies
In force
 · High confidence
In forceHigh confidence
US 8,420,084Fully Human Antibodies Specific to CADM1
In force
 · High confidence
In forceHigh confidence
US 12,157,757Cation Exchange Chromatography Methods
In force
 · Medium confidence
In forceMedium confidence
US 9,758,593Compositions and methods for treating cocaine-related disorders
In force
 · Medium confidence
In forceMedium confidence
Also on record, not counted in the 9: 2 patents in force now held by others · 45 patents ended · 10 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
5 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited